Exclusive Summary

• Cilostazol offers a multi-mechanistic approach to comprehensively improve microcirculation, positioning it as an attractive first-line or preferred therapy for PAD and secondary prevention of ischemic stroke.
• Clinical evidence robustly supports its significant improvement in walking distance for intermittent claudication patients and effective reduction of restenosis, amputation, and target lesion revascularization.
• Compared to aspirin, cilostazol demonstrates superior efficacy in preventing ischemic stroke recurrence with a lower risk of cerebral hemorrhage, providing a safer and more effective treatment option.
• Endorsed by multiple authoritative international and national guidelines, confirming its established efficacy and facilitating market access and prescription by physicians.
• Presents substantial commercial potential by addressing unmet needs in millions of PAD and high-risk ischemic stroke patients, with its low bleeding risk likely to drive broad adoption in vulnerable populations.

Asset Materials

Contact Us for Full Materials